Untargeted Metabolomics and Quantitative Analysis of Tryptophan Metabolites in Myalgic Encephalomyelitis Patients and Healthy Volunteers: A Comparative Study Using High-Resolution Mass Spectrometry. — CFSMEATLAS
Untargeted Metabolomics and Quantitative Analysis of Tryptophan Metabolites in Myalgic Encephalomyelitis Patients and Healthy Volunteers: A Comparative Study Using High-Resolution Mass Spectrometry.
Abujrais, Sandy, Vallianatou, Theodosia, Bergquist, Jonas · ACS chemical neuroscience · 2024 · DOI
Quick Summary
Researchers compared blood chemistry between 38 people with ME/CFS and 24 healthy people to understand what might be different in their bodies. They found several chemical imbalances, particularly in how the body processes tryptophan (an amino acid) and in pathways related to energy production and inflammation. These differences suggest that ME/CFS patients may experience unusual immune activity and stress damage to their cells.
Why It Matters
This study provides objective biochemical evidence that ME/CFS involves measurable metabolic dysfunction, potentially validating patient experiences and supporting the biological basis of the condition. Identifying specific metabolic abnormalities could eventually lead to biomarkers for diagnosis and targeted treatments.
Observed Findings
Significantly elevated 3-hydroxyanthranilic acid levels in ME/CFS patients compared to healthy controls
Significantly elevated 3-hydroxykynurenine levels in ME/CFS plasma
Increased hypoxanthine levels in ME/CFS patients
Altered phenylalanine levels in ME/CFS group
Disruption of vitamin B3, arginine-proline, and aspartate-asparagine metabolic pathways
Inferred Conclusions
ME/CFS is associated with dysregulation in tryptophan metabolism and downstream immune-related pathways
Oxidative stress and immune system dysfunction appear to be biochemically evident in ME/CFS patients
Multiple interconnected metabolic pathways are disrupted rather than a single isolated defect
Metabolomic profiling may help distinguish ME/CFS from healthy controls at a biochemical level
Remaining Questions
Do these metabolic changes vary across ME/CFS subtypes or severity levels, and can they predict disease progression?
Are these metabolic abnormalities present in all ME/CFS patients or only specific subgroups?
What This Study Does Not Prove
This study does not prove that these metabolic changes cause ME/CFS symptoms or that correcting them will improve patient outcomes. The cross-sectional design only shows associations at a single time point and cannot establish causation or whether these changes are primary defects or secondary effects of the disease.
Do these metabolic alterations improve with successful treatments, and if so, which changes correlate with symptom recovery?
What are the upstream causes of these metabolic disruptions—viral infection, genetic factors, environmental triggers, or post-viral immune dysregulation?